Investors & Media

Investors & Media

Investors

About Be the Match BioTherapies

Magenta and Be The Match BioTherapies have initiated a collaboration to support their shared goals of improving transplant medicine. Magenta and Be The Match BioTherapies will explore opportunities to work together across all of Magenta’s research efforts, from discovery through clinical development. Under this agreement, Magenta may leverage Be The Match BioTherapies’ capabilities, including its cell therapy delivery platform, industry relationships, clinical trial design and management, and patient outcomes data derived from the NMDP/Be The Match, which operates the largest and most diverse marrow registry in the world. NMDP/Be The Match has a network of more than 486 organizations that support marrow transplant worldwide, including 178 transplant centers in the United States and more than 45 international donor centers and cooperative registries.

Press Releases

December 11, 2017
Magenta Therapeutics’ Expanded Stem Cell Product, MGTA-456, Engrafts in 100% of Patients, Leading to Robust Neutrophil and Immune Recovery in Two Phase 2 Clinical Studies

December 11, 2017
Magenta Therapeutics Presents Preclinical Data from Stem Cell Mobilization and Expansion Programs

December 9, 2017
Magenta Therapeutics’ Lead Targeted Antibody Drug Conjugate Shows Promising Preclinical Results for Non-Genotoxic Conditioning for Bone Marrow Transplant

December 7, 2017
New Data Published in Journal Cell Show Robust Mobilization of Highly Engraftable Stem Cells in Mouse Models with Combination of GROβ and Plerixafor

View All Press Releases

Media Contacts

For media inquiries, please contact:
Manisha Pai, Vice President of Communications and Investor Relations
mpai@magentatx.com

Social Media

Twitter
LinkedIn

Awards